Bright Minds Biosciences and Firefly Neuroscience to Collaborate …
1 day ago · Forward-looking statements in this news release include design, progress, and completion of the BREAKTHROUGHStudy, future clinical development of BMB-101, and future intended use or therapeutic benefit of BMB-101 to treat refractory epilepsy disorders. A variety of factors, including known and unknown risks, many of which are beyond our control ...
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A …
Sep 12, 2024 · BMB-101 offers a differentiated treatment option for patients with refractory epilepsy, where current therapies often fall short, and could provide a new standard of care for a much wider population of epilepsy sufferers.
Bright Minds Biosciences Announces Positive Topline Data
Jul 20, 2023 · BMB-101, a highly selective 5-HT 2C, Gq-protein biased agonist, has demonstrated compelling activity in a host of in vitro and in vivo nonclinical tests. Compared to Lorcaserin, BMB-101...
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A …
Sep 12, 2024 · Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs; BMB-101 is a novel highly selective 5-HT2C...
Bright Minds Biosciences and Firefly Neuroscience to Collaborate …
1 day ago · Forward-looking statements in this news release include design, progress, and completion of the BREAKTHROUGHStudy, future clinical development of BMB-101, and future intended use or therapeutic ...
Bright Minds Biosciences Announces Positive qEEG (Quantitative ...
Aug 7, 2023 · BMB-101, a highlyselective 5-HT 2C, Gq-protein biased agonist, has demonstrated compelling activity in a host of in vitro and in vivo nonclinical tests. Compared to Lorcaserin, BMB-101 exhibits strong Gq biased signaling, coupled with minimal beta-arrestin recruitment.
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A
Sep 12, 2024 · Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy. BMB-101 is a novel highly selective 5-HT2C agonist. Its G-protein biased agonism provides an improved mechanism of action for chronic dosing.
Bright Minds Biosciences proprietary compound, BMB-201, 5 …
5 days ago · BMB-201, a selective 5-HT2A/2C receptor agonist, was designed to harness the analgesic potential of serotonin modulation without the hallucinogenic effects commonly associated with 5-HT2A...
New BREAKTHROUGH Study of BMB-101, Positive Phase 1 Data …
Sep 21, 2024 · According to an announcement from Bright Minds Biosciences, the company has initiated a new phase 2 study, dubbed BREAKTHROUGH, that will assess the safety and efficacy of its investigational agent BMB-101 in adults with classic absence epilepsy and development epileptic encephalopathy (DEE).
Newly Initiated Phase 2 BREAKTHROUGH Trial to Test 5-HT2C …
Sep 16, 2024 · BMB-101, a 5-HT2C receptor agonist, will be tested in a cohort of 20 adults aged 18 to 65 with absence epilepsy or a developmental encephalopathy for an 8-to-12-week treatment period.
- Some results have been removed